GlaxoSmithKline

GlaxoSmithKline

GlaxoSmithKline (GSK)GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit www.gsk.com.

GlaxoSmithKline RSS Channel

Filters
List of articles in category GlaxoSmithKline
Title Published Date
GlaxoSmithKline and Human Genome Sciences receive positive opinion in Europe from the CHMP for Benlysta® (belimumab) 24 May 2011
Pharmaceutical industry and university create Manchester Collaborative Centre for Inflammation Research 12 May 2011
Unique Research Alliance Expands Collaboration Opportunities 13 April 2011
GSK statement on Avodart™ (dutasteride) for prostate cancer risk reduction 28 March 2011
GSK outlines new plan to drive recruitment and attract graduate talent in the UK 03 March 2011
GSK's full year trading update 03 February 2011
GSK and Valeant receive positive opinion for Trobalt (retigabine) 24 January 2011
GSK responds to 60 Minutes | Related Video 03 January 2011
GSK to strengthen Nutritional Healthcare business with acquisition of Maxinutrition 13 December 2010
GlaxoSmithKline and JSC Binnopharm enter vaccine production alliance in Russia 28 November 2010
GSK, Fondazione Telethon and Fondazione San Raffaele to collaborate on gene therapy 19 October 2010
GlaxoSmithKline receives EU approval for a new therapeutic indication for Arixtra® 01 October 2010
GSK regulatory update on Avandia following EMA and FDA reviews 27 September 2010
BBC Panorama: "A Risk Worth Taking?" Programme. GlaxoSmithKline Right of Reply Statement 07 September 2010
Reports of narcolepsy in Europe following vaccination with Pandemrix™ 06 September 2010
GSK European Commission amends licence for Cervarix® 25 August 2010
GSK receives CHMP positive opinion for a new indication for Arixtra 26 July 2010
GSK EU regulatory update on Avandia (rosiglitazone) 12 July 2010
GlaxoSmithKline enters agreement with Medivir for exclusive rights to cold sore treatment Xerclear™ 24 June 2010
GlaxoSmithKline receives conditional marketing authorisation in the EU for Arzerra® (ofatumumab) 21 April 2010
p-312_300x250